Polycythemia Vera

SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best available therapy in patients with high-risk polycythemia vera, according to data presented at ASH Annual Meeting.

In this video, John Mascarenhas, MD, discussed the RuxoBEAT study into ruxolitinib treatment in patients with polycythemia vera, which was presented at the ASH Annual Meeting and Exposition.

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), discussed a case study, presented at the 14th International Congress on Myeloproliferative Neoplasms, of dizygotic twins.

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), highlighted phase 2 data investigating hepcidin mimetics for polycythemia vera that appears to have eliminated the need for phlebotomy.

Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s European Hematology Association Congress.

In this video, Aaron T. Gerds, MD, MS, discusses critical takeaways from the REVEAL study presented at ASH Annual Meeting and Exposition.

Direct oral anticoagulant use appeared linked to high incidence of bleeding among patients with myeloproliferative neoplasms, according to study results presented at ASH Annual Meeting & Exposition.

Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit below 45% without phlebotomy, according to a study presented at ASH Annual Meeting and Exposition.

The FDA approved ropeginterferon alfa-2b-njft for the treatment of adults with polycythemia vera.

Patients acquired myeloproliferative neoplasm driver mutations early in life, often in utero, which then expanded at variable rates over their lifetime before diagnosis, according to study results.